Subscribe to news

Cell Processing Equipment Distribution

Cytori Therapeutics, Inc. (USA)Distribution of the products of Cytori Therapeutics, Inc. (USA)

In 2011, Human Stem Cells Institute (HSCI) signed an exclusive distribution contract with the US-based Cytori Therapeutics for marketing and sales in Russia of Celution® System.

The device automates and standardizes the extraction, washing, and concentration of a patient’s own adipose-derived regenerative cells (ADRCs), which can then be redelivered to the same individual in a surgical procedure for reconstructive and aesthetic medicine. The isolated cells can also be stored for future use.

The device allows for lipofilling, a procedure used in aesthetic medicine to correct cosmetic defects on the face or body as well as for rejuvenation and creation of new contours via injection of ADRCs.

Celution® System combines conceptually new ideas in regenerative personalized medicine and cell-based technologies and provides previously unimaginable opportunities in plastic surgery, for example, reconstructive breast surgery using one's own cultured cell tissues rather than silicone implants. This technology has been used on more than 5,000 patients in Europe and Japan.

The use of automated cell isolation methods is a key trend in cell-based technologies as is the use of one’s own cells with minimal manipulations. The “Auto and Fresh” approach alleviates the problem of material logistics in an isolated laboratory as sample sterility and the number of procedures necessary. The liposuction procedure can be conducted, ADRCs isolated and lipofilling procedure completed all within one and a half hours on the operating table. This is a very quick and compact process compared to the use of external laboratories.

HSCI received the marketing authorization in Russia in May 2012 and started distribution activities in Q4 2012.

Press-release (June 1, 2012)
HSCI Receives Authorization for Innovative Technology Using Fat Tissue in Reconstructive Surgery